pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›calendar
  3. ›phase readout
phase readout
save

NCT06896916: Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma

RECRUITING$ABBVupdated 6mo ago
community read0 votes

Sponsor: AbbVie. Phase: PHASE1. Conditions: Multiple Myeloma

view source ↗
Data sources
ctgov
last refreshed 4h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

same company · ±60 days · 6

  • earningsAbbVie Inc. earningsOct 30, 2026
  • earningsAbbVie Inc. earningsOct 29, 2026
  • earningsAbbVie Inc. earningsJul 31, 2026
  • earningsAbbVie Inc. earningsJul 30, 2026
  • phase 1 2 completionblinatumomab: AbbVie Inc — blinatumomab (Phase I/II Trial Completion)Apr 30, 2026
  • phase 1 2 completionvenetoclax: AbbVie Inc — venetoclax (Phase I/II Trial Completion)Apr 30, 2026

related news · 8

  • biospaceFDA’s Summit rejection puts PD-1xVEGF class on notice to establish overall survival↗
  • fiercebiotechFDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class↗
  • biopharma diveAt ASH, drugmakers to showcase early data for three-pronged cancer therapies↗
  • fiercebiotechAbbVie abandons phase 2 solid tumor drug over ‘limited benefit’↗
  • biospaceAbbVie’s skin disease drug lessens abscess burden in Phase 3 but falls below expectations↗
  • fiercebiotechAbbVie scratches out phase 3 hidradenitis suppurativa win but falls short of expectations↗
  • biospaceAs AbbVie’s Crohn’s combo beats Skyrizi in mid-stage test, analysts laud autoimmune vision↗
  • endpointsAbbVie’s Skyrizi combo beats Skyrizi alone in mid-stage Crohn’s trial↗

🐶 often sniffed alongside

top 8
  • tagApproval168 co-mentions · 84 sources
  • drugHUMIRA122 co-mentions · 61 sources
  • drugadalimumab122 co-mentions · 61 sources
  • drugABRILADA61 co-mentions · 61 sources
  • drugYUSIMRY61 co-mentions · 61 sources
  • drugAMJEVITA61 co-mentions · 61 sources
  • drugSKYRIZI46 co-mentions · 23 sources
  • drugrisankizumab46 co-mentions · 23 sources

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?